Balance Sheet
Cash Flow Statement
Cash from Discontinued OperationsCash from Discontinued OperationsCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Account PayablesChange in Account PayablesChange in CashChange in ReceivablesChange in ReceivablesDepreciation & Amortization (CF)Depreciation & Amortization (CF)Depreciation and DepletionDepreciation and DepletionExchange Rate EffectExchange Rate EffectFree Cash FlowFree Cash FlowNet Cash FlowNet Cash FlowNet IncomeOther Working Capital ChangesOther Working Capital ChangesShare-based CompensationShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Addex Therapeutics (ADXN) Share-based Compensation (2019 - 2025)

Addex Therapeutics' Share-based Compensation history spans 7 years, with the latest figure at -$30.1 billion for Q2 2025.

  • On a quarterly basis, Share-based Compensation rose 92.95% to -$30.1 billion in Q2 2025 year-over-year; TTM through Jun 2025 was $3.6 billion, a 100.35% increase, with the full-year FY2025 number at $85418.0, down 85.12% from a year prior.
  • Share-based Compensation came in at -$30.1 billion for Q2 2025, down from $27.7 billion in the prior quarter.
  • The five-year high for Share-based Compensation was $1025.2 billion in Q2 2023, with the low at -$1584.2 billion in Q4 2023.
  • Historically, Share-based Compensation has averaged $407.5 million across 5 years, with a median of $575348.5 in 2023.
  • Peak annual rise in Share-based Compensation hit 149772522.7% in 2023, while the deepest fall reached 222878623.25% in 2023.
  • Year by year, Share-based Compensation stood at $297509.3 in 2021, then surged by 138.92% to $710802.1 in 2022, then tumbled by 222878623.25% to -$1584.2 billion in 2023, then soared by 66.01% to -$538.5 billion in 2024, then soared by 94.41% to -$30.1 billion in 2025.
  • Business Quant data shows Share-based Compensation for ADXN at -$30.1 billion in Q2 2025, $27.7 billion in Q1 2025, and -$538.5 billion in Q4 2024.